PreciDIAB

The Hauts-de-France has set up a National Center for Precision Medicine in the Lille metropolitan area around the topic of diabetes

The State has approved an allocation of 5 million for the financing of the National Center for Precision Medicine for Diabetes (PreciDIAB). Supported from the start by the CHU and the University of Lille and led by Professor Philippe Froguel, renowned researcher and current director of the European Institute of Diabetes Genomics (EGID), this project aims to make the Lille site a global research center for the treatment and prevention of obesity and diabetes, for the benefit of Hauts-de-France thanks to the development of collaborations between the University Hospital of Amiens and the University Hospital of Lille. This project mobilizes, in addition to the State endowment, more than 15 million euros in subsidies from the European Metropolis of Lille (€ 11 million) voted last Friday, from Amiens Métropole (€ 1 million), from the Hauts-Region. de-France and the FEDER (€ 4 million) in addition to the € 51 million of equity provided in particular by the CHU and the University of Lille.

Logo horizontal PreciDIAB

Diabetes, a major public health issue

Overweight and obesity affect an estimated 1.4 billion people worldwide, a number expected to exceed 3 billion by 2030 according to WHO forecasts. Risk factors for many chronic diseases including diabetes, overweight and obesity are a scourge with major economic and medical consequences. Steadily increasing, the number of diabetics in the world now reaches 425 million. An estimated 5 million people died of diabetes in 2015, significantly more than AIDS, tuberculosis and malaria combined. In France, 3.3 million people are affected and medically monitored, or around 5% of the population. To these people monitored, we must add 20 to 25% of undiagnosed people, which brings the number of diabetics in France to more than 4 million.

Challenges and skills in Hauts-de-France

With a rate of 6.2%, the Hauts-de-France region has the highest prevalence in mainland France. Diabetes is therefore a major public health issue and a priority research area for the entire national territory and especially in Hauts-de-France. In 2009, three renowned researchers – Professors Philippe Froguel, François Pattou and Bart Staels – decided to create EGID, the first research institute in France dedicated specifically to diabetes and its complications. This European Institute for Diabetes Genomics is unique in France and in 2011 obtained the LABoratoire d’EXcellence (Labex) label, renewed in 2019 for 5 additional years.

The PreciDiab project supported by the State and local actors

As an extension of this dynamic, the PreciDIAB project was selected by the University and the University Hospital of Lille to respond, in 2017, to the second call for projects “Hospital-University Institutes” (IHU2) of the Future Investments Program (PIA). Led by Philippe Froguel, director of the EGID Labex, the excellence of the project was recognized by the international jury and PreciDIAB was awarded the National Center for Precision Medicine for diabetes, along with PRISM and THEMA, respectively for solid cancers ( Villejuif) and leukemia (Paris) with an allocation of 5 million Euros for each of the National Centers. The National Research Agency (ANR) has today formalized this allocation following the signing, on September 23, of a consortium agreement uniting seven establishments around the PreciDIAB project: the I-SITE Université Lille Nord- Europe, the Center Hospitalier Universitaire de Lille, the University of Lille, the Institut Pasteur de Lille, the Center Hospitalier Universitaire Amiens-Picardie, the Francophone Society of Diabetes, the French Federation of Diabetics and the Eurasanté Economic Interest Group.

Towards the creation of a multidisciplinary clinical research center

Developing new means of prevention, care and treatment of diabetic patients in order to counter the disease and its consequences, this is the objective of the creation of the PreciDIAB Center. This center aims to develop new medical approaches, based on scientific data and innovation to develop prevention and precision medicine for the future. By bringing together specialists from all disciplines related to diabetes, PreciDIAB aspires to develop a translational and multidisciplinary method for the management of diabetes which will be tested in the Lille and Amiens metropolitan areas and then in all Hauts-Hauts-de-Seine. de-France, with a view to future distribution throughout the country.
The objective is to create a network of care for the future around and with the diabetic patient, in order to prevent diabetes complications and adverse drug effects, and to offer individualized follow-up, tailored to the patient and his needs. To achieve this objective, it is necessary to be able to identify patients at risk of complications during their lifetime, and to be able to predict the modes of development of diabetes, to anticipate the complications and acute episodes that are the source of hospitalization, in the framework of more personalized medicine.
 
This project will strengthen the attractiveness of Lille and contribute to the development of collaborations between the University Hospital of Amiens and the University Hospital of Lille for the benefit of Hauts-de-France for the reception of new research centers and teams, ‘pharmaceutical, diagnostic and e-health industries. The PreciDIAB Initiative industrial club brings together all diabetes players. Supported in particular by the Entreprises et Cités endowment fund, this club aims to create a dynamic of innovation and develop public-private partnerships.
 
Source: Diabetes Atlas IDF 8th Edition 2017
 
Source: Public Health France, 27-28, November 2018
 

Download CP